Month: August 2025

Second quarter consolidated revenues were $4.7 billion on lower industry demand Second quarter diluted EPS at $0.17 Results reflect continued execution of cost saving initiatives partially offsetting market headwinds Returned $0.3 billion to shareholders through dividends Full-year guidance reaffirmed Basildon, UK – August 1, 2025 – CNH Industrial N.V. (NYSE: CNH) today reported results for the three months ended June 30, 2025, with net income of $217 million and diluted earnings per share of $0.17 compared with net income of $404 million and diluted earnings per share of $0.32 for the three months ended June 30, 2024(1). Consolidated revenues were $4.71 billion (down 14% compared to Q2 2024), and net sales of Industrial Activities were $4.02 billion (down 16% compared to Q2 2024). Net cash provided by operating activities...

HOUSTON and LONDON, Aug. 01, 2025 (GLOBE NEWSWIRE) —Net income: $115 million, $202 million excluding identified items1 Diluted earnings per share: $0.34 per share; $0.62 per share excluding identified items EBITDA: $606 million, $715 million excluding identified items Cash from operating activities: $351 million Returned $536 million to shareholders through dividends and share repurchases Continued to execute on strategy while navigating the cycle with operational and financial discipline:Announced the planned sale of select European assets to further optimize the business portfolio Deferring construction of Flex-2 project to preserve capital during the cycle downturn Cash Improvement Plan on track to achieve an increased run-rate of $600 million dollars for 2025 while expanding into 2026 with an incremental target of $500...

Second quarter 2025 revenues increased 4% to $3.68 billion versus second quarter 2024 Dupixent® global net sales (recorded by Sanofi) increased 22% to $4.34 billion EYLEA HD® U.S. net sales increased 29% to $393 million; total EYLEA HD and EYLEA® U.S. net sales decreased 25% to $1.15 billion GAAP EPS increased 3% to $12.81; non-GAAP EPS(a) increased 12% to $12.89 FDA approved Lynozyfic™ (linvoseltamab) for relapsed or refractory multiple myeloma and Dupixent for bullous pemphigoid and chronic spontaneous urticaria (CSU) FDA accepted for priority review Libtayo® sBLA for adjuvant cutaneous squamous cell carcinoma (CSCC) In-licensed rights to late-stage dual GLP-1/GIP receptor agonist; reported interim 26-week data from Phase 2 COURAGE trial in obesityTARRYTOWN, N.Y., Aug. 01, 2025 (GLOBE NEWSWIRE) — Regeneron Pharmaceuticals,...

21,017 vehicles were delivered in July 2025 135,167 vehicles were delivered year-to-date in 2025, increasing by 25.2% year-over-year Cumulative deliveries reached 806,731 as of July 31, 2025SHANGHAI, Aug. 01, 2025 (GLOBE NEWSWIRE) — NIO Inc. (NYSE: NIO; HKEX: 9866; SGX: NIO) (“NIO” or the “Company”), a pioneer and a leading company in the global smart electric vehicle market, today announced its July 2025 delivery results. The Company delivered 21,017 vehicles in July 2025. The deliveries consisted of 12,675 vehicles from the Company’s premium smart electric vehicle brand NIO, 5,976 vehicles from the Company’s family-oriented smart electric vehicle brand ONVO, and 2,366 vehicles from the Company’s small smart high-end electric car brand FIREFLY. Cumulative deliveries reached 806,731 as of July 31, 2025. Our smart large-space...

Strong second quarter performance reflected disciplined execution and operational excellence Comparing the second quarter of 2025 to the second quarter of 2024:Sales decreased 3% to $10.6 billion, as light vehicle production declined 6% and 2% in North America and Europe, respectively Income from operations before income taxes increased 16% to $496 million Adjusted EBIT increased 1% to $583 million and Adjusted EBIT margin improved 20 basis points to 5.5% Diluted earnings per share of $1.35 and Adjusted diluted earnings per share of $1.44 increased 24% and 7%, respectivelyReturned $324 million to shareholders in dividends and share repurchases in the first half of 2025, including $137 million in dividends during the second quarter Updated 2025 outlook, including increases to Total Sales, Adjusted EBIT Margin, and Adjusted Net Income...

ZUG, Switzerland, Aug. 01, 2025 (GLOBE NEWSWIRE) — Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs, today announced that it has amended its loan facility (the “Amended Loan Agreement”) with funds and accounts managed by BlackRock (the “Lender”). The Amended Loan Agreement replaces the prior loan agreement between Oculis and the Lender dated May 29, 2024, and the upsized structure will provide CHF 75.0 million in borrowing capacity (which may be increased to up to CHF 100.0 million) (the “Loan”).  The Loan comprises tranches 1, 2 and 3, in the amounts of CHF 25.0 million each, as well as an additional loan of up to CHF 25.0 million, which may be made available...